Evidaxia

JCA Pulse › Timeline

JCA timeline

EU JCA timeline: every upcoming milestone

Regulatory decisions, JCA reports and national HTA steps, in date order.

Every dated milestone for the technologies in EU joint clinical assessment: regulatory decisions, JCA reports and the national HTA steps that follow. 14 milestones are coming up; the list was last checked on 5 November 2026.

Filter by your market in the tracker

Coming up

November 2026

  1. EarlyNovTovorafenib (Ojemda)Paediatric low-grade gliomaG-BA resolution scheduledsourceGermany
  2. 10NovTarlatamab (Imdylltra)ES-SCLC after first-line platinumG-BA oral hearingsourceGermany
  3. 10NovLurbinectedin (Zepzelca)ES-SCLC, first-line maintenanceG-BA oral hearingsourceGermany
  4. 10NovTarlatamab (Imdylltra)ES-SCLC after first-line platinumNICE committee meeting (second line, ID6617)sourceUnited Kingdom
  5. 12NovTaletrectinibROS1-positive NSCLCNICE scope consultation closessourceUnited Kingdom
  6. 23NovOnasemnogene abeparvovec, intrathecal (Itvisma)5q spinal muscular atrophy, age 2+G-BA written comments closesourceGermany
  7. 25NovOnasemnogene abeparvovec, intrathecal (Itvisma)5q spinal muscular atrophy, age 2+NICE guidance expected (ID6556)sourceUnited Kingdom
  8. DueNovTarlatamab (Imdylltra)ES-SCLC after first-line platinumAssessment board recommendation expectedsourceAustria
  9. DueNovLurbinectedin (Zepzelca)ES-SCLC, first-line maintenanceAssessment board recommendation expectedsourceAustria

December 2026

  1. DueDecTarlatamab (Imdylltra)ES-SCLC after first-line platinumG-BA resolution expectedsourceGermany
  2. DueDecLurbinectedin (Zepzelca)ES-SCLC, first-line maintenanceG-BA resolution expectedsourceGermany

January 2027

  1. 13JanTarlatamab (Imdylltra)ES-SCLC after first-line platinumNICE guidance expected (ID6617)sourceUnited Kingdom
  2. EndJanOnasemnogene abeparvovec, intrathecal (Itvisma)5q spinal muscular atrophy, age 2+G-BA resolution expectedsourceGermany

February 2027

  1. 24FebTarlatamab (Imdylltra)ES-SCLC after first-line platinumMedicines Council decision expectedsourceDenmark

Last 90 days

  1. 2NovOnasemnogene abeparvovec, intrathecal (Itvisma)5q spinal muscular atrophy, age 2+G-BA assessment publishedsourceGermany
  2. 16OctTarlatamab (Imdylltra)ES-SCLC after first-line platinumMedicines Council assessment startedsourceDenmark
  3. 13OctLurbinectedin (Zepzelca)ES-SCLC, first-line maintenanceNICE terminated appraisal published (TA1198)sourceUnited Kingdom
  4. 8OctTarlatamab (Imdylltra)ES-SCLC after first-line platinumNCPE rapid review: full HTA recommendedsourceIreland
  5. 2OctSAPIEN M3 transcatheter mitral valve replacement systemMitral regurgitation, unsuitable for surgery or TEERSelected for JCAsourceEU
  6. 2OctHighLife trans-septal mitral valve replacement systemMitral regurgitation, unsuitable for surgery or TEERSelected for JCAsourceEU
  7. 1OctTarlatamab (Imdylltra)ES-SCLC after first-line platinumG-BA assessment publishedsourceGermany
  8. 1OctLurbinectedin (Zepzelca)ES-SCLC, first-line maintenanceG-BA assessment publishedsourceGermany
  9. 18SepOnasemnogene abeparvovec, intrathecal (Itvisma)5q spinal muscular atrophy, age 2+NT Council: wait for TLV assessmentsourceSweden
  10. 18SepSenaparib (Sepalna)Ovarian cancer, first-line maintenanceCHMP positive opinionsourceEU
  11. 18SepRelacorilant (Lifyorli)Platinum-resistant ovarian cancerCHMP positive opinionsourceEU
  12. 17SepEnsartinib (Gevalka)ALK-positive NSCLCCHMP positive opinionsourceEU
  13. 17SepLurbinectedin (Zepzelca)ES-SCLC, first-line maintenanceHAS declined early accesssourceFrance
  14. 16SepSintilimabNon-squamous NSCLCJCA discontinuedsourceEU
  15. 14SepAutologous TIL (Tacquell)MelanomaEU marketing authorisation refusedsourceEU
  16. 10SepSAPIEN M3 transcatheter mitral valve replacement systemMitral regurgitation, unsuitable for surgery or TEERHAS backs Forfait Innovation coveragesourceFrance
  17. 9SepOnasemnogene abeparvovec, intrathecal (Itvisma)5q spinal muscular atrophy, age 2+HSE CPU: company proposal under reviewsourceIreland
  18. 7SepOnasemnogene abeparvovec, intrathecal (Itvisma)5q spinal muscular atrophy, age 2+JCA report publishedsourceEU

JCA reports published

  1. 7SepOnasemnogene abeparvovec, intrathecal (Itvisma)5q spinal muscular atrophy, age 2+JCA report published · 12 PICOsEU
  2. 8JulTarlatamab (Imdylltra)ES-SCLC after first-line platinumJCA report published · 7 PICOsEU
  3. 8JulLurbinectedin (Zepzelca)ES-SCLC, first-line maintenanceJCA report published · 1 PICOsEU
  4. 9JunTovorafenib (Ojemda)Paediatric low-grade gliomaJCA report published · 8 PICOsEU

How the JCA timeline works

  • 12 January 2025JCAs began for new cancer medicines and advanced therapy medicinal products (ATMPs).
  • 2026Selected high-risk medical devices and in vitro diagnostics entered joint clinical assessment.
  • 13 January 2028Orphan medicinal products are added to the scope.
  • 13 January 2030All new medicines authorised through the centralised procedure are in scope.

Under Regulation (EU) 2021/2282, the JCA report is due within 30 days of the EU marketing authorisation decision. Member states then take it into account in their national HTA and pricing processes.